Depressive Disorder, Mental Disorder in Adolescence
Conditions
Keywords
Aromatic Herbs, Volatile oils, Inhalation via the nose
Brief summary
In this study, 60 depressed patients who meet the criteria will randomly be divided into a test group and a control group, with 30 patients in each group. The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation and the control group will be given Bergamot for inhalation. The observation indicators are that after one and two sessions of the intervention, the patients' blood pressure, heart rate, depression scale scores, and changes in functional near-infrared spectroscopy(fNIRS). This randomized controlled trial will be used to look at the clinical efficacy of CAVO in patients with depression.
Detailed description
Depression is a common psychiatric disorder characterised by persistent depressed mood, loss of interest and feelings of helplessness. Depression has the highest burden of illness of any mental illness and is the leading cause of disability. Currently, depression is usually treated with antidepressants as the first line of treatment, but because the pathophysiological mechanisms of depression are still unclear, the mechanisms of antidepressant treatment are unknown, and there is no objective way to predict efficacy, depression often requires multiple trial and error treatments before an effective treatment plan can be determined. Chemically synthesised drugs are widely used to treat depression, but side effects have become a bottleneck to their long-term use. As a result, natural products from medicinal plants, such as Essential oils or Volatile oils, have become research targets for the development of new drugs. Volatile oil of Cang-Ai is a component extracted from aromatic Chinese herbs such as Atractlodis Rhizoma, Herba Agastaches, Flos Caryophylli, which is commonly used clinically in the treatment of mood disorders. This study will use a randomised controlled study method. 60 patients with depression who attended the First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine from March 2022 to September 2022 will be recruited. They will be randomly divided into a trial group and a control group, 30 patients in each group. The test group will be given Volatile oil of Cang-Ai for inhalation and the control group will be given Bergamot for inhalation. Ultimately, a number of indicators will be tested to assess the clinical efficacy of the volatile oil of Cang-Ai.
Interventions
DRUGVolatile Oil of Cang-Ai
The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
DRUGBergamot essential oils
The control group will be given Bergamot essential oils for inhalation.
Sponsors
Jieqiong Cui
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 28 Years
Healthy volunteers
No
Inclusion criteria
* Meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for depressive episodes. * Beck Depression Scale \>10; 24-item Hamilton Depression Scale (HAMD) score \>20 * Healthy sense of smell, no allergic diseases, respiratory diseases, age 16-40 years, male or female. * No use of antidepressants and other psychiatric drugs or physiotherapy such as electroconvulsive shock or transcranial magnetic stimulation (TMS) for at least 1 week prior to the intervention ⑤All subjects volunteered to participate and signed an informed consent form after approval by the hospital's ethics committee
Exclusion criteria
* History of schizophrenia, alcohol and drug dependence strictly excluded ②Depression with a history of organic brain disease and endocrine disorders or secondary to other psychiatric disorders * Score \>3 on the Hamilton Depression Inventory for Suicide ④Pregnant and breastfeeding women with a history of manic or hypomanic episodes ⑤Family history of monophasic or bipolar disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from functional near-infrared spectroscopy（fNIRS) at 28 days | At the end of Cycle 1 (each cycle is 14 days) | Functional near-infrared spectroscopy to measure changes in the relative concentrations of Oxy-Hb and Deoxy-Hb in the cerebral cortex (prefrontal and temporal lobes) |
| 24-item Hamilton Depression Inventory scores | At the end of Cycle 1 (each cycle is 14 days) | The following severity ranges for the HAMD: no depression (0-7); mild depression (8-16); moderate depression (17-23); and severe depression (≥24) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from blood pressure | At the end of Cycle 1 (each cycle is 14 days) | Patients' blood pressure will be measured by a blood pressure monitor |
| Change from blood pressure at 28 days | At the end of Cycle 2 (each cycle is 14 days) | Patients' blood pressure will be measured by a blood pressure monitor |
| Change from heart rate | At the end of Cycle 1 (each cycle is 14 days) | Patients' heart rate will be measured by a heart rate monitor |
| Change from heart rate at 28 days | At the end of Cycle 2 (each cycle is 14 days) | Patients' heart rate will be measured by a heart rate monitor |
Outcome results
None listed